Shares of the following companies are showing unusual moves in Monday's trading session .
Among the winners, Inhibitex is being acquired by Bristol-Myers Squibb for $2.5 billion, which represents a 163 percent premium over Friday's close.
To the downside, Theravance fell on news that Relovair, a GlaxoSmithKline drug developed in the US by Theravance, had some mixed clinical results.
By The Numbers | Stocks on the Move Now
